Johnson & Johnson (NYSE:JNJ) Stock Holdings Lifted by Skyline Advisors Inc.

Skyline Advisors Inc. lifted its holdings in Johnson & Johnson (NYSE:JNJ) by 3.5% during the first quarter, according to the company in its most recent filing with the SEC. The fund owned 2,478 shares of the company’s stock after buying an additional 83 shares during the quarter. Skyline Advisors Inc.’s holdings in Johnson & Johnson were worth $392,000 as of its most recent filing with the SEC.

Other large investors also recently modified their holdings of the company. Keener Financial Planning LLC bought a new stake in Johnson & Johnson in the 4th quarter valued at about $40,000. WFA Asset Management Corp lifted its position in Johnson & Johnson by 61.4% in the 4th quarter. WFA Asset Management Corp now owns 255 shares of the company’s stock valued at $40,000 after purchasing an additional 97 shares during the last quarter. Vermillion & White Wealth Management Group LLC bought a new stake in Johnson & Johnson in the 4th quarter valued at about $44,000. Disciplined Equity Management Inc. bought a new stake in Johnson & Johnson in the 4th quarter valued at about $45,000. Finally, Grayhawk Investment Strategies Inc. lifted its position in Johnson & Johnson by 528.6% in the 4th quarter. Grayhawk Investment Strategies Inc. now owns 308 shares of the company’s stock valued at $48,000 after purchasing an additional 259 shares during the last quarter. 69.55% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several brokerages recently weighed in on JNJ. Cantor Fitzgerald reiterated an “overweight” rating and issued a $215.00 price objective on shares of Johnson & Johnson in a research report on Monday. StockNews.com upgraded shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Sunday. Royal Bank of Canada restated an “outperform” rating and set a $175.00 price target on shares of Johnson & Johnson in a research report on Monday, June 17th. The Goldman Sachs Group started coverage on shares of Johnson & Johnson in a research report on Thursday, May 30th. They set a “neutral” rating and a $160.00 price target on the stock. Finally, Morgan Stanley dropped their price target on shares of Johnson & Johnson from $168.00 to $167.00 and set an “equal weight” rating on the stock in a research report on Wednesday, April 17th. Eight equities research analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $174.07.

Johnson & Johnson Stock Performance

Shares of JNJ opened at $146.03 on Wednesday. The firm’s 50 day moving average is $148.09 and its 200-day moving average is $153.97. The stock has a market capitalization of $351.45 billion, a P/E ratio of 9.10, a P/E/G ratio of 2.43 and a beta of 0.52. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.17 and a quick ratio of 0.94. Johnson & Johnson has a 12-month low of $143.13 and a 12-month high of $175.97.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Tuesday, April 16th. The company reported $2.71 earnings per share for the quarter, topping the consensus estimate of $2.64 by $0.07. The business had revenue of $21.38 billion for the quarter, compared to the consensus estimate of $21.39 billion. Johnson & Johnson had a net margin of 45.26% and a return on equity of 36.70%. The firm’s quarterly revenue was up 2.3% compared to the same quarter last year. During the same period last year, the firm posted $2.68 earnings per share. Equities research analysts anticipate that Johnson & Johnson will post 10.62 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, June 4th. Stockholders of record on Tuesday, May 21st were given a $1.24 dividend. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.19. This represents a $4.96 annualized dividend and a dividend yield of 3.40%. The ex-dividend date was Monday, May 20th. Johnson & Johnson’s dividend payout ratio (DPR) is 30.92%.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.